Study guide
6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy
Key Takeaways Explain This Topic AI
Immune Checkpoint Inhibitors (ICIs) target negative regulatory pathways—PD-1 (pembrolizumab, nivolumab), PD-L1 (atezolizumab, durvalumab), and CTLA-4 (ipilimumab)—to reactivate endogenous cytotoxic T-lymphocytes against tumor cells.
Immune-related adverse events (irAEs) result from loss of self-tolerance and T-cell hyperactivation; early identification and prompt administration of systemic corticosteroids (prednisone 1-2 mg/kg/day equivalent) are essential for Grade 2–4 toxicities.
Steroid-refractory irAEs require second-line immunosuppressive agents tailored to the organ affected: infliximab or vedolizumab for refractory colitis; mycophenolate mofetil for refractory hepatitis.
CAR T-cell therapy utilizes genetically re-engineered autologous T-cells expressing a synthetic chimeric antigen receptor (scFv + costimulatory CD28/4-1BB + CD3z) to target cell-surface antigens (e.g., CD19, BCMA) independent of MHC presentation.
Management of Cytokine Release Syndrome (CRS) and ICANS follows ASTCT grading protocols: CRS with persistent fever and hypotension/hypoxia requires tocilizumab (IL-6 receptor antagonist) ± dexamethasone; ICANS management prioritizes high-dose dexamethasone due to poor central nervous system penetration of tocilizumab.
Last updated: August 2026
4.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy
Immuno-oncology has revolutionized cancer management by leveraging the host immune system to recognize and eradicate tumor cells. Unlike cytotoxic chemotherapy or targeted therapies that act directly on tumor cell machinery, immunotherapies target immune regulatory pathways or genetically re-engineer immune effector cells. For the Advanced Oncology Certified Nurse Practitioner (AOCNP®), an in-depth understanding of immune checkpoint blockade, the spectrum and management of immune-related adverse events (irAEs), and the specialized protocols for Chimeric Antigen Receptor (CAR) T-cell therapy—including toxicities like Cytokine Release Syndrome (CRS) and neurotoxicity—is critical for safe patient care.
1. Immune Checkpoint Inhibitor (ICI) Biology & Targets
Tumor cells evade host immune surveillance by exploiting endogenous immune checkpoints —surface receptors that normally maintain peripheral self-tolerance and limit collateral tissue damage during inflammatory responses. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block these inhibitory interactions, restoring cytotoxic T-lymphocyte activation and anti-tumor activity.
Core Checkpoint Receptor Pathways
CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Blockade : CTLA-4 regulates T-cell activation early within lymph nodes during the priming phase. It competes with the costimulatory receptor CD28 for binding to B7-1 (CD80) and B7-2 (CD86) ligands on antigen-presenting cells (APCs). Ipilimumab (anti-CTLA-4 mAb) blocks CTLA-4, allowing unrestrained T-cell proliferation and priming. Because CTLA-4 acts broadly in systemic immune priming, ipilimumab carries a higher incidence of severe immune toxicities.
PD-1 (Programmed Cell Death Protein 1) Blockade : PD-1 operates primarily in peripheral tissues during the effector phase of T-cell responses. Activated T-cells express PD-1; when bound to its ligands ( PD-L1 or PD-L2 ) expressed on tumor cells or tumor-infiltrating macrophages, PD-1 transmits an inhibitory signal that induces T-cell exhaustion and unresponsiveness. Monoclonal antibodies targeting PD-1 ( pembrolizumab, nivolumab, cemiplimab ) prevent ligand binding and re-energize exhausted tumor-infiltrating lymphocytes.
PD-L1 Blockade : Monoclonal antibodies targeting the PD-L1 ligand on tumor cells ( atezolizumab, durvalumab, avelumab ) selectively disrupt the PD-1/PD-L1 interaction while preserving PD-1 binding to PD-L2, potentially reducing specific inflammatory side effects.
2. Clinical Management of Immune-Related Adverse Events (irAEs)
Disrupting immune checkpoint pathways leads to a distinct spectrum of autoimmune-like toxicities termed immune-related adverse events (irAEs) . irAEs can affect any organ system, most commonly appearing within 2 to 16 weeks of initiating treatment, though delayed onset can occur months after drug discontinuation.
Organ System Common irAE Manifestations Clinical Symptoms & Diagnostic Markers
Gastrointestinal Immune-mediated colitis, enteritis Frequent watery diarrhea (≥ 4 stools/day above baseline), abdominal pain, hematochezia, mucosal ulceration on colonoscopy
Pulmonary Immune-mediated pneumonitis Cough, progressive dyspnea, fever, hypoxia, focal or diffuse ground-glass opacities on chest CT
Dermatologic Maculopapular rash, pruritus, vitiligo, Stevens-Johnson syndrome (SJS/TEN) Erythematous rash, mucosal erosion, skin sloughing
Endocrine Hypophysitis, thyroiditis, adrenal insufficiency, Type 1 diabetes Fatigue, headache, visual field defects, hyponatremia, TSH suppression/elevation, morning cortisol < 3 mcg/dL, diabetic ketoacidosis
Hepatic Immune-mediated hepatitis Asymptomatic AST/ALT elevations, elevated total bilirubin
Cardiovascular Immune-mediated myocarditis Troponin elevation, arrhythmias, heart block, heart failure; high mortality rate
Common Terminology Criteria for Adverse Events (CTCAE) Management Algorithm
Grade 1 (Mild; asymptomatic or mild symptoms) : Continue ICI with close clinical and laboratory monitoring (except for cardiac, neurologic, or hematologic toxicities, which prompt immediate hold).
Grade 2 (Moderate; minimal non-invasive intervention indicated) : Hold ICI . Initiate oral systemic corticosteroids ( prednisone 0.5–1 mg/kg/day or equivalent). Upon symptom improvement to Grade ≤ 1, taper steroids slowly over 4 to 6 weeks before considering ICI resumption.
Grade 3–4 (Severe or life-threatening) : Permanently discontinue ICI (in most cases). Immediately hospitalize patient and initiate high-dose corticosteroids ( intravenous methylprednisolone 1–2 mg/kg/day or equivalent).
Steroid-Refractory irAEs : If no clinical improvement occurs within 48 to 72 hours of high-dose corticosteroids, initiate second-line immunosuppressive agents:
Refractory Colitis : Infliximab (5 mg/kg IV) or vedolizumab (300 mg IV).
Refractory Hepatitis : Mycophenolate mofetil (500–1000 mg PO/IV BID). Note: Infliximab is contraindicated in severe hepatic injury due to hepatotoxicity risk.
Refractory Myocarditis : High-dose pulse methylprednisolone (1000 mg IV daily for 3 days) plus antithymocyte globulin (ATG), infliximab, or abatacept.
3. Chimeric Antigen Receptor (CAR) T-Cell Therapy Architecture
CAR T-cell therapy represents an advanced cellular immunotherapy wherein autologous T-cells are harvested via leukapheresis, genetically transduced using a viral vector to express a synthetic Chimeric Antigen Receptor (CAR) , expanded ex vivo, and re-infused into the patient following lymphodepleting conditioning chemotherapy.
CAR Structure Components
Extracellular Antigen-Binding Domain : Single-chain variable fragment (scFv) derived from a monoclonal antibody that targets specific surface antigens in a major histocompatibility complex (MHC)-independent manner.
Transmembrane Domain : Anchors the receptor to the T-cell membrane.
Intracellular Signaling Domain : Contains a primary T-cell activation domain ( CD3-zeta ) combined with one or more costimulatory domains ( CD28 or 4-1BB / CD137 ). Costimulatory domains enhance T-cell proliferation, persistent survival, and memory formation in vivo.
FDA-Approved Targets
CD19-Directed CAR T-Cells ( tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel ): Indicated for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, and follicular lymphoma.
BCMA (B-Cell Maturation Antigen)-Directed CAR T-Cells ( idecabtagene vicleucel, ciltacabtagene autoleucel ): Indicated for relapsed/refractory multiple myeloma.
4. ASTCT Protocols for Acute CAR T-Cell Complications
Prior to CAR T-cell infusion, patients receive lymphodepleting chemotherapy (typically fludarabine 30 mg/m² daily plus cyclophosphamide 500 mg/m² daily for 3 days) to eradicate endogenous lymphocytes and create a favorable cytokine niche (elevated IL-7, IL-15) for CAR T expansion. Systemic toxicities managed under American Society for Transplantation and Cellular Therapy (ASTCT) consensus guidelines include:
A. Cytokine Release Syndrome (CRS)
CRS is a systemic inflammatory response triggered by massive CAR T-cell activation and proliferation, resulting in excessive production of pro-inflammatory cytokines, predominantly interleukin-6 (IL-6) , interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α).
ASTCT CRS Grade Clinical Criteria Interventional Management Protocol
Grade 1 Temperature ≥ 38.0°C; no hypotension; no hypoxia Supportive care: antipyretics (acetaminophen), IV hydration, empirical broad-spectrum antibiotics for neutropenic fever.
Grade 2 Temp ≥ 38.0°C; hypotension responding to fluid bolus OR hypoxia requiring low-flow nasal cannula (≤ 6 L/min) Administer tocilizumab 8 mg/kg IV (max 800 mg) over 1 hour. Repeat q8h if no response (max 4 doses). Consider dexamethasone 10 mg IV.
Grade 3 Temp ≥ 38.0°C; hypotension requiring one vasopressor OR hypoxia requiring high-flow nasal cannula or mask Tocilizumab 8 mg/kg IV plus dexamethasone 10–20 mg IV q6h . Transfer to ICU; vasopressor titration.
Grade 4 Temp ≥ 38.0°C; hypotension requiring multiple vasopressors OR hypoxia requiring mechanical ventilation / CPAP Tocilizumab 8 mg/kg IV plus dexamethasone 20 mg IV q6h or methylprednisolone 1000 mg IV daily. ICU care.
B. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
ICANS results from cytokine-mediated blood-brain barrier disruption and microglial activation. Early signs include dysgraphia (inability to write a standard sentence), expressive aphasia, confusion, tremors, motor weakness, and cerebral edema.
Diagnostic Assessment : Perform the 10-point Immune Effector Cell Encephalopathy (ICE) score screening every 8 hours (evaluating orientation, naming, following commands, writing, and concentration).
Grade 1 ICANS (ICE score 7–9) : Supportive care; hold sedatives; perform neurology consult and non-contrast head CT.
Grade 2 ICANS (ICE score 3–6) : Initiate dexamethasone 10 mg IV every 6 to 12 hours . Note: Tocilizumab does not effectively cross the blood-brain barrier and is NOT indicated for isolated ICANS unless concurrent CRS is present.
Grade 3–4 ICANS (ICE score 0–2, seizures, or cerebral edema) : Administer dexamethasone 20 mg IV every 6 hours or high-dose IV methylprednisolone (1000 mg/day). Manage status epilepticus with levetiracetam or lorazepam.